遗传信息,基因组技术,以及药物发现的未来
1Research Technologies and Proteins (DC0444), Lilly Research Laboratories, A Division of Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA. bumol@lilly.com
JAMA
|February 15, 2001
概括
人类基因组草案使我们能够理解疾病遗传学. 新技术,如转录分析,通过识别未来制药的分子标来帮助药物发现.
科学领域:
- 基因组学就是基因组学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类基因组项目为了解遗传疾病提供了基础.
- 生物技术的进步,包括转录分析,提供了高分辨率的分子分析.
- 目前的药物发现重点是识别和验证分子途径内的标.
研究的目的:
- 为疾病研究利用基因组信息和新技术.
- 在分子系统中识别和验证药物标.
- 开发和评估新的治疗干预措施.
主要方法:
- 使用人类基因组序列的第一个草稿.
- 采用先进的生物技术,如成绩单分析.
- 分析分子路径和系统以识别目标.
主要成果:
- 了解疾病的遗传基础的前所未有的机会.
- 能够以高分子分辨率检查生物系统.
- 识别潜在的药物目标.
结论:
- 基因组洞察力和技术进步正在推动制药创新.
- 新的治疗干预措施正在从这项研究中出现.
- 这项工作构成了未来创新药物的基础.
相关概念视频
Next-generation Sequencing
101.9K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
101.9K
Drug Discovery: Overview
13.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.5K
Pharmacogenetics and Pharmacogenomics: Overview
180
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
180
Principles of Pharmacogenetics: Types of Genetic Variants
113
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
113
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
126
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
Pharmacogenomics: Identification of New Drug Targets
92
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92


